Open Label Extension In Cancer Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

October 29, 2009

Primary Completion Date

February 14, 2013

Study Completion Date

February 14, 2013

Conditions
NeoplasmsBone Metastases
Interventions
BIOLOGICAL

Anti-NGF AB

Solution for injection, 10 mg, one injection/8 weeks

Trial Locations (23)

8003

Fejer Megyei Szt. Gyorgy Korhaz - Rendelointezet/Aneszteziologiai es Intenziv Betegellato Osztaly, Székesfehérvár

42000

General Hospital Varazdin, Varaždin

71105

WK River Cities Clinical Research Center, Shreveport

78000

Clinic of Oncology, Banja Luka

84112

Huntsman Cancer Institute, Salt Lake City

92093

UCSD Moores Cancer Center, La Jolla

226003

Chhatrapati Shahuji Maharaj Medical University, Lucknow

92037-7651

UCSD Center for Pain Medicine, La Jolla

UCSD Medical Center - Thornton Hospital, La Jolla

UCSD Periman Ambulatory Care Center, La Jolla

A-3541

Nuhr Zentrum, Senftenberg

440 010

Central India Cancer Research Institute Central India Cancer Research Institute, Nagpur

422 005

Shatabdi Super Speciality Hospital, Nashik

LV-1079

Latvian Oncology Centre, Riga

85-796

Niepubliczny Zaklad Opieki Zdrowotnej, Bydgoszcz

80-208

Hospicjum im Ks Eugeniusza Dutkiewicza SAC w Gdansku, Gdansk

61-245

**Poradnia Medycyny Paliatywnej, Hospicjum Palium, Poznan

61-866

Wielkopolskie Centrum Onkologii im. Marii Sklodowskiej-Curie, Poznan

87-800

NZOZ Zespol Opieki Domowej Polskiego Towarzystwa Opieki Paliatywnej, Włocławek

975 17

Fakultna Nemocina s Poliklinikou FD Roosevelta Banska Bystrica, Banská Bystrica

833 10

Narodny onkologicky ustav, Bratislava

120-752

Severance Hospital, Yonsei University College of Medicine, Seodaemun-gu

135-710

Samsung Medical Center, Division of Hematology-Oncology, Department of Medicine, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00830180 - Open Label Extension In Cancer Patients | Biotech Hunter | Biotech Hunter